Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients.
Sarah BesoraCristina SantosCristina IzquierdoMaria Mercedes Martinez-VillacampaJordi BrunaRoser VelascoPublished in: Journal of cancer research and clinical oncology (2018)
Retreatment with OXA in CRC patients is a feasible option even in patients who previously developed moderate or severe OIN. One-third of patients' OIN was worsened by retreatment. Neurological monitoring should be considered.